The y-aminobutyrate-synthesizing enzyme glutamate decarboxylase (GAD; L-glutamate 1-carboxy-lyase, EC 4.1.1.15) is a major target of autoantibodies associated with both early and late stages of pancreatic ,B-cell destruction and development of type 1 diabetes. We have used five monoclonal anti-islet-cell antibodies (MICAs 1, 2, 3, 4, and 6) derived from a newly diagnosed diabetic patient to probe the autoimmune epitopes in the enzyme. All the MICAs specificafly recognized the smaller GAD protein, GAD6O, and did not recognize the nonallelic GAD67 protein. A series of N-terminal, C-terminal, and internal deletion mutants, as well as protein footprinting, were used to identify the target regions in GAD6s. Immunoprecipitation revealed two major native epitope areas in the
Glutamate decarboxylase (GAD; EC 4.1.1.15) is encoded by two distinct nonallelic genes, specifying GAD65 and GAD67 (subscripts indicate approximate molecular mass in kilodaltons), that may have developed from a common ancestral gene during vertebrate phylogeny. Thus Drosophila has only one gene encoding GAD, which is similarly homologous to each of the mammalian forms (1) . GAD67 and GAD65 are highly diverse in the first 95 amino acids but share significant homology (-78% identity) in the rest of the molecule. Both have a proteolytic hotspot 80-90 amino acids from the N terminus (2, 3) , which may represent a domain boundary. The N-terminal region harbors the posttranslational modifications which result in anchoring of GAD65 to the membrane of synaptic vesicles and control the distinct subcellular localization of this protein (3) . Drosophila GAD lacks most of the N-terminal amino acid residues, suggesting that this domain evolved to provide GAD65 and GAD67 with their distinct targeting to subcellular compartments, a feature which may have implications for both function and autoantigenicity (3) . Some species express both GAD proteins in their pancreatic islets (2) . In human islets only GAD65 is expressed (4, 5) , in contrast to brain, where both GAD65 and GAD67 are produced (6). GAD65 is a major target of circulating IgG autoantibodies in two human diseases that affect the sites of GAD expression: type 1 diabetes, which is caused by an autoimmune destruction of pancreatic (3 cells (7), and a rare neurological disorder, stiff-man syndrome (8) , in which -aminobutyrate-secreting neurons are impaired. GAD-reactive T cells have been demonstrated in type 1 diabetes (9, 10) . The GAD65 antibodies seem to be the earliest marker of autoimmune reactions directed to the (3 cell and are sometimes present up to several years before clinical onset (11, 12) . Although (3-cell destruction is likely to be T-cell-mediated (13) , the autoantibodies present during the early phases of 3-cell destruction are important for two reasons. First, it is likely that such antibodies are directed to the same target antigen as pathogenic T cells. Second, the antibodies identify individuals at risk of developing type 1 diabetes.
Most diabetic sera recognize only conformational epitopes in the GAD65 molecule and do not react with the denatured protein on Western blots. In contrast sera from patients with stiff-man syndrome recognize denatured GAD65 (7) . Recently, Richter et al. (14) derived a number of Epstein-Barr virus-immortalized B-cell lines from the peripheral blood of newly diagnosed type 1 diabetic patients. Stable IgGproducing monoclonal B-cell lines positive for islet-cell antibodies by indirect immunofluorescence staining of frozen sections of human pancreas were stabilized following repeated single-cell cloning. All the monoclonal anti-islet-cell antibodies (MICAs) were directed to GAD (14) . In this study we show that the target epitopes are specific for GAD65 and identify the regions of the molecule that harbor the autoantigenic target epitopes for the monoclonal antibodies. We have furthermore addressed the question whether the MICAs represent an epitope recognition characteristic for autoantibodies to GAD in type 1 diabetes.
MATERIALS AND METHODS Antisera. Supernatants of human monoclonal B-cell lines containing MICAs 1-6 were prepared as described (14) . Mouse mAb GAD1 (15) , which recognizes native forms of GAD65 and GAD67, was obtained from the American Type Culture Collection. Mouse monoclonal antibody GAD6 (16) and rabbit polyclonal antibodies 1266 and K2 (2, 3) were described earlier. Serum from a patient with stiff-man syndrome was donated by Vanda Lennon (Mayo Clinic, RochAbbreviations: GAD, glutamate decarboxylase; MICA, monoclonal anti-islet-cell antibody; PAS, protein A-Sepharose. *To whom reprint requests should be addressed at: Hormone Re- search Institute, University of California, San Francisco, CA 94143-0534.
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Proc. Natl. Acad. Sci. USA 90 (1993) 2833 ester, MN). Sera from type 1 diabetic patients were obtained from H. J. Aanstoot (University of Rotterdam, The Netherlands) or described earlier (11) . Expression of GAD in Baculovirus Expression Systems. Recombinant baculovirus vectors expressing human GAD65 and GAD67 were constructed by ligating a 1.8-kb BamHI fragment of a human GAD65 cDNA clone into the BamHI site of the baculovirus vector pVL941 (a gift from D. Morgan, University of California, San Francisco) and a 2.7-kb EcoRI fragment of human GAD67 into the EcoRI site of the baculovirus vector pVL1392 (Invitrogen, San Diego). An N-terminal deletion mutant lacking the first 101 amino acids (aa) of rat GAD65 was generated by oligonucleotide-directed mutagenesis (17) and inserted into pVL1392 (Y.S. and S.B., unpublished work). GAD cDNAs were a gift from A. Tobin (University of California, Los Angeles). Recombinant viruses were derived and isolated as described (3) . Recombinant baculovirus harboring full-length rat GAD65 was described earlier (3).
Expression of Wild Type and Mutants of Rat GAD65 in COS-7 Cells. Rat GAD65 cDNA was subcloned into the Kpn I and Not I sites of the pSV-SPORT vector (BRL) for expression in a COS-7 cell line (American Type Culture Collection). A collection of N-terminal and C-terminal deletion mutants of GAD65 was generated by polymerase chain reaction (18) at predetermined sites, using anchored primers (Y.S. and S.B., unpublished work). Expression was analyzed by Western blotting with GAD6 (N-terminal mutants) and a stiff-man-syndrome serum (C-terminal mutants). An internal deletion mutant lacking aa 363-422 was generated by using 7.4/10 mM benzamidine/150 mM NaCl/0.5 mM methionine/ 0.01% bovine serum albumin/5 mM EDTA/0.1 mM phenylmethylsulfonyl fluoride/0.5% Triton X-114 and was followed by SDS/PAGE analysis and fluorography.
RESULTS
All MICAs Specifically Recognize Native GAD65 but Not GAD67 in Immunoprecipitation Experiments. GAD65 is identical to the 64-kDa autoantigen in type 1 diabetes, and previous analyses of GAD antibodies using islet-cell lysates have focused on this form of GAD (11, 12, 20, 21) . Some sera may also recognize GAD67, but analysis of antibodies to this protein in human sera are still hampered by background problems (unpublished results). We first addressed the question whether the set of MICAs derived from a type 1 diabetic patient (MICAs 1-6) recognize human GAD65 and/or GAD67 proteins expressed in Sf9 insect cells or in COS-7 cells under native conditions. MICAs 1, 2, 3, 4, and 6 recognized GAD65 but not GAD67 in immunoprecipitation experiments under native conditions using PAS (Fig. 1 ). MICA 5, the only MICA of subclass IgG3, did not bind PAS. MICA 5, however, showed specific binding to GAD65 and did not recognize GAD67 in immunoprecipitates isolated with protein G-Sepharose (results not shown). Since MICA 5 bound only weakly to protein G-Sepharose and seemed to recognize an epitope similar to that of MICA 2 in preliminary experiments, it was not included in further analysis. The absence of reactivity with GAD67 suggests that the MICA epitopes are defined by amino acids which differ between GAD65 and GAD67. Serum of the type 1 diabetic patient from whom MICAs 1-6 were derived was also strongly positive for antibodies recognizing human GAD65 but showed only a weak reactivity with human GAD67 (results not shown), consistent with the specificity of these monoclonal antibodies.
Only MICA 2 Recognizes a Linear Epitope in GAD65. In contrast to stiff-man-syndrome sera, which recognize denatured GAD65 on Western blots, sera from most type 1 diabetic patients only recognize conformational epitopes in the GAD molecule (7). When we analyzed the reactivity of the individual MICAs for denatured GAD65 and GAD67, only MICA 2 recognized denatured GAD65 on Western blots. Furthermore, when we tested serum of the type 1 diabetic patient from whom MICAs 1-6 were derived, it weakly stained denatured GAD65 but not GAD67 on Western blots (results not shown).
The results above show that MICAs 1, 3, 4, and 6 recognize only nonlinear or conformational epitopes, whereas MICA 2 recognizes a linear epitope that is specific for GAD65. Thus GAD65 harbors linear as well as nonlinear or conformational autoimmune epitopes that distinguish it from GAD67.
Protein Footprinting Reveals Two to Four Distinct Epitopes.
The similarities and differences in epitope recognition by the MICAs were analyzed by protein footprinting (19) . These analyses revealed two major different footprinting patterns which distinguished MICAs 1-3 from MICAs 4 and 6. Within the first group MICAs 1 and 3 displayed identical patterns which were similar to yet distinct from that of MICA 2. Further, in the second group MICAs 4 and 6 displayed only minor differences (Fig. 2) . Both MICA 4 and MICA 6 more effectively protected the full-length GAD65 molecule and a 55-kDa fragment lacking the N terminus than did MICAs 1-3. Thus, in contrast to MICAs 4 and 6, no full-length GAD65 or 55-kDa fragment was detected in immunocomplexes with MICAs 1-3 after prolonged chymotrypsin incubation (Fig. 2 , compare lanes 10 and 11 with lanes 7 and 9). These results suggest that MICAs 4 and 6 may bind areas of the molecule closer to the N terminus and therefore protect this part ofthe molecule better than MICAs 1-3.
While MICAs 1, 3, 4, and 6 still displayed a complex footprinting pattern following prolonged incubations with chy- (Fig. 2, lanes 7-12) , only one band of -14 kDa was protected by MICA 2 under those conditions (Fig. 2, lane 8) .
In sum, the complex footprinting patterns of MICAs 1, 3, 4, and 6 are consistent with a nonlinear epitope recognition, whereas the 14-kDa single fragment protected by MICA 2 is consistent with a linear epitope recognition by this monoclonal antibody. Further, the footprinting results suggest that MICAs 4 and 6 may recognize areas more toward the N terminus than those recognized by MICAs 1-3.
Distinct Patterns of Recognition of Deletion Mutants by MICAs. To localize the domains recognized by the MICAs, we analyzed their binding to a number of N-terminal as well as C-terminal deletion mutants of rat GAD65 expressed in COS-7 cells (Fig. 3) . The sizes of the expressed GAD65 fragments, their location in the amino acid sequence, and their reactivity with the various MICAs are summarized in Fig. 3C . The first N-terminal deletion mutant which was recognized differently from the full-length protein was GAD65N33 (A1-295). This mutant was not recognized by MICAs 1, 4, and 6 and was either very weakly positive or negative with MICA 3 (Fig. 3 A and C) . MICA 2 reacted equally well with GAD65N33 and the full-length molecule on Western blots. However, MICA 2 reacted only weakly with this form in immunoprecipitation experiments ( Fig. 3 A and  C) , suggesting that the linear epitope recognized by this monoclonal antibody is sequestered in the folded truncated protein.
Analysis of C-terminal deletion mutants showed that the removal of 41 aa at the C terminus abolished the binding of MICAs 1-3 ( Fig. 3 B and C) . However, MICAs 4 and 6 recognized both this mutant (GAD65C61, A545-585) and the C-terminal deletion mutant GAD65C53 (A476-585), which lacks an additional 69 aa at the C terminus ( Fig. 3 B and C) . MICA 4 showed a stronger binding to both mutants than MICA 6. None of the MICAs showed reactivity to the C-terminal deletion mutant GAD65C41 (A376-585), which is missing an additional 100 aa at the C terminus (Fig. 3C) .
None pyridoxal phosphate binding site of the enzyme or a hybrid molecule containing aa 1-95 from GAD67 linked to the last 233 aa of GAD65 (Fig. 3C) . It can be concluded that amino acids within the last 41 residues of GAD65 are a significant part of the linear epitope for MICA 2. Analysis of Sera from Type 1 Diabetic Patients. All the MICAs were derived from a single newly diagnosed diabetic individual. Since this patient's serum showed reactivity with GAD65 on Western blots, a feature which is rare among sera from type 1 diabetic individuals, it was of importance to establish whether the immune recognition pattern of the MICAs is shared by other type 1 diabetic individuals. Sera from young newly diagnosed type 1 diabetic patients (D1-9), ages 41/2-26 years (6 female, 3 male), and a prediabetic individual (P1), age 11 years (female), were analyzed for their binding to the N-terminal and C-terminal deletion mutants (Fig. 4) . Two of the sera (D6 and D7) reacted very weakly with the full-length molecule and were therefore not suitable for epitope analysis. The remaining prediabetic/diabetic sera, which were strongly positive for GAD65 antibodies, displayed similar reactivity toward the N-terminal deletion mutants. Thus, deletion of approximately one-third (A1-194) of the GAD65 molecule from the N terminus did not result in a detectable decrease in immunoreactivity with the prediabetic/diabetic sera, and deletion of an additional 50 aa at the N terminus (GAD65N39) resulted in only a slightly decreased reactivity with some of the sera (Fig. 4) . In contrast, further deletion of 51 aa (GAD65N33) abolished recognition by all of the sera (results not shown). The sera proved distinguishable in the analysis of the mutant lacking 41 aa at the C terminus (GAD65C61). Thus, four sera-including the serum from the prediabetic individual sampled 32 months before clinical onset of disease, as well as sera from three newly diagnosed patients [an 11-year-old girl (D3), a 41/2-year old boy (D4), and a 26-year-old man (D5)], all of which were strongly positive for GAD65 antibodies-showed either very weak or no reactivity with the GAD65C61 mutant (Fig. 4) . The remainder of the sera were still strongly positive for this truncated protein (Fig. 4) . The results are consistent with the data obtained with the MICAs and suggest that humoral epitopes associated with type 1 diabetes are concentrated in the middle and C-terminal domains of GAD65. Our data are in agreement with a previous study, which showed that antibodies to an -50-kDa tryptic fragment of GAD65 correlate completely with antibodies to the full-length GAD65 molecule in type 1 diabetic patients (22, 23) . The tryptic fragment lacks the N-terminal 80-90 aa but contains the C terminus (3). None of the 11 patient sera recognized GAD65 on Western blots and thus did not contain autoantibodies with a linear epitope recognition such as MICA 2 (results not shown).
DISCUSSION
The N-Terminal Region Is Not the Site of Autoimmune Epitopes in GAD65. GAD67 and GAD65 are highly diverse in   FIG. 4 . The MICAs represent common epitopes among type 1 diabetic patients. N-terminal and C-terminal deletion mutants of rat GAD65 were used for immunoprecipitation analysis with sera from nine newly diagnosed diabetic patients (D1-9), a prediabetic individual sampled 32 months before clinical onset of disease (P1), the patient whose B-cells yielded the MICAs (D10), a GAD65 antibody-and islet-cell cytoplasmic antibody-positive individual with no clinical symptoms of type 1 diabetes (P2), and two healthy individuals (Cl and C2). A 1-244 the first 95 aa but share significant homology in the rest of the molecule. However, none of the GAD6s-specific epitopes recognized by the MICAs were localized in the first 244 aa at the N terminus. Thus, the epitopes of the MICAs are concentrated in areas of the molecule that are significantly distant from the N-terminal membrane-anchoring domain. The last 110 aa at the C terminus do not contribute to the MICA 4/6 epitope(s), which spans residues in the middle of the molecule. In contrast deletion of 41 aa at the C terminus abolishes the MICA 1/3 epitope. Furthermore, deletion of aa 245-295 abolishes all the conformational epitopes. Since deletions in one part of a protein molecule can significantly alter the conformation in distant parts of the molecule, it is not clear whether residues among aa 245-295 as well as 545-585 are part of the MICA 1/3 epitope or whether they are important for the conformation of the MICA 1/3 epitope, without having a direct involvement in binding. Indirect evidence, however, supports the explanation that the C-terminal region is the major site of the MICA 1/3 epitope. The protein footprinting patterns of MICAs 1 and 3 are very similar to that of MICA 2, which recognizes an epitope in this region, but clearly distinct from those of MICAs 4 and 6, which recognize an epitope or epitopes in the middle of the molecule. Furthermore, deletion of aa 245-295 (GAD65N33 mutant) seems to result in major conformational changes in the C-terminal region, as suggested by the weak binding of MICA 2 to this mutant, whereas deletion of aa 545-585 and 476-585 in the C terminus does not seem to affect the middle region of the GAD65 molecule, where the MICA 4 and 6 epitopes remain intact. Finally, MICA 3 did bind weakly to the GAD65N33 mutant, whereas no binding to the C-terminal deletion mutants was detected. Thus deletion of aa 244-295 is likely to be affecting the conformation of the C-terminal region, whereas deletion of the C-terminal amino acids appears to affect the MICA 1/3 epitope directly.
The MICA 2 Epitope. MICA 2 was the only MICA which recognized the GAD65 molecule on Western blots. This reactivity represents a rare case of recognition of linear epitopes by autoantibodies from type 1 diabetic patients. This linear epitope recognition by MICA 2 was confined to the C-terminal domain, which also seems to be important for the conformational epitope of MICAs 1 and 3. Consequently the protein footprint of MICA 2 was highly similar to those of MICAs 1 and 3. A significant part of the linear MICA 2 epitope is localized between aa 545 and 585-i.e., close to the C terminus. We have also identified and characterized a linear epitope that is recognized by 20 of 21 (95%) sera of stiff-man-syndrome patients and shown that it is clearly distinct from that of MICA 2 (unpublished results). This clear difference in epitope recognition between the two diseases suggests that the humoral autoimmunity to GAD is not only an epiphenomenon of the autoimmune process but related to the pathogenic mechanisms which result in either stiff-man syndrome or type 1 diabetes. The results of this study will contribute to the development of assays for GAD65 autoantibodies in type 1 diabetes for prediction and diagnosis. First, they demonstrate the importance of intact conformation of the middle and C-terminal parts of the molecule. Further, the data indicate that the N-terminal region, with its lipid modifications, is dispensable and can either be deleted to improve the solubility of the protein or be used as a site for immobilization and other modifications without affecting the humoral autoantigenic epitopes in type 1 diabetes. Lipid modification of peptides and proteins can, however, play a major role in T-cell responses (27, 28) , and the N-terminal region of GAD65 may still harbor important T-cell epitopes. 
